In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 9, 2003, Pages 3025-3029

  Bemer, Pascale ^a   Juvin, Marie Emmanuelle ^a   Bryskier, Andre ^b   Drugeon, Henri ^a  

^a HÔTEL DIEU   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CALCIUM ION; DAPTOMYCIN; HMR 1043; LIPOPEPTIDE; TEICOPLANIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CORRELATION COEFFICIENT; DRUG STRUCTURE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; LISTERIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; CALCIUM; DIFFUSION; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; MUTATION; PEPTIDES, CYCLIC;

EID: 0042423602     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.9.3025-3029.2003     Document Type: Article

References (13)

1. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
2. Coudron, P. E., J. L. Johnson, and G. L. Archer. 1987. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis. J. Antimicrob. Chemother. 20:505-511.
3. Ehlert, F., and H. C. Neu. 1987. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur. J. Clin. Microbiol. 6:84-90.
4. Eliopoulos, G. M., S. Willey, E. Reiszner, P. G, Spitzer, G. Caputo, and R, C. Moellering. 1986. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.
5. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38:51-58.
6. Jones, R. N., and A. L. Barry. 1987. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. 31:625-629.
7. Louie, A., A. L. Baltch, W. J. Ritz, R. P. Smith, and M. Asperilla. 1993. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 39:302-310.
8. Mobarakai, N., J. M. Quale, and D. Landman. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387.
9. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial susceptibility tests, 6th ed. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.
12. Snydman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450.
13. Szybalski, W, 1952. Microbial selection. I. Gradient plate technique for study of bacterial resistance. Science 116:46-48.